Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18928649 | OPIOID FORMULATIONS | October 2024 | March 2025 | Allow | 4 | 1 | 0 | No | No |
| 18441413 | MAGNESIUM BIOTINATE COMPOSITIONS AND METHODS OF USE | February 2024 | February 2025 | Allow | 12 | 0 | 1 | No | No |
| 18500595 | OPIOID FORMULATIONS | November 2023 | July 2024 | Allow | 9 | 1 | 2 | No | No |
| 18500603 | OPIOID FORMULATIONS | November 2023 | June 2025 | Abandon | 19 | 2 | 0 | Yes | Yes |
| 18476562 | BILAYER BIONIC DRUG-LOADED HYDROGEL, AND PREPARATION AND APPLICATION THEREOF | September 2023 | October 2024 | Abandon | 12 | 2 | 0 | No | No |
| 18130706 | Antimicrobial Articles | April 2023 | April 2025 | Abandon | 25 | 2 | 1 | No | No |
| 18189010 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | March 2023 | May 2025 | Allow | 26 | 2 | 1 | No | No |
| 18109718 | ENTERIC AEROBIZATION THERAPY | February 2023 | August 2024 | Allow | 18 | 3 | 0 | No | No |
| 18059108 | NOVEL COMPOSITION BASED ON POLYCAFFEOYLQUINIC ACIDS, COSMETIC USE THEREOF AND COSMETIC COMPOSITIONS COMPRISING SAME | November 2022 | October 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17983784 | COSMETIC POWDER COMPOSITE AND COSMETIC COMPOSITION CONTAINING SAME | November 2022 | April 2025 | Abandon | 29 | 2 | 1 | Yes | No |
| 17902805 | PERSONAL CARE COMPOSITIONS | September 2022 | October 2024 | Allow | 26 | 2 | 0 | No | No |
| 17815972 | STEM CELL STIMULATING COMPOSITIONS AND METHODS | July 2022 | January 2025 | Abandon | 30 | 4 | 1 | No | No |
| 17782466 | Encapsulated fragrance compounds based on natural amino acids | June 2022 | July 2025 | Allow | 37 | 0 | 1 | No | No |
| 17749470 | SUNSCREEN COMPOSITIONS CONTAINING A COMBINATION OF A LINEAR ULTRAVIOLET RADIATION-ABSORBING POLYETHER AND OTHER ULTRAVIOLET-SCREENING COMPOUNDS | May 2022 | November 2024 | Allow | 30 | 4 | 0 | No | No |
| 17738771 | Method and System for Increasing Beneficial Bacteria and Decreasing Pathogenic Bacteria in the Oral Cavity | May 2022 | December 2024 | Allow | 31 | 1 | 1 | No | No |
| 17773087 | STABILIZATION OF DIMPROPYRIDAZ SUSPENSIONS BY TRIETHYLAMMONIUM CHLORIDE | April 2022 | December 2024 | Allow | 32 | 0 | 0 | No | No |
| 17731534 | LIPID DEPOT FORMULATIONS | April 2022 | February 2025 | Abandon | 33 | 2 | 1 | No | No |
| 17768876 | CHEMICAL MODIFICATION OF SILK FIBROIN FOR FABRICATION OF ENZYMATICALLY CROSSLINKED HYDROGELS WITH TUNABLE GELATION KINETICS AND BIOACTIVITY | April 2022 | April 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17753814 | DRIFT CONTROL ADJUVANT FORMULATION CONTAINING A SULFOPOLYMER | March 2022 | April 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17689506 | High-Efficiency Transdermal Patches | March 2022 | January 2025 | Abandon | 35 | 3 | 0 | No | No |
| 17612512 | COMPOSITION COMPRISING SORBITOL OR XYLITOL, AND A GELLING AGENT | November 2021 | April 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17501463 | JAB1 Inhibitory Compositions for Ossification and Methods Related Thereto | October 2021 | April 2025 | Allow | 42 | 4 | 0 | No | No |
| 17382893 | COMPOSITION COMPRISING A UV-SCREENING AGENT, AN ANIONIC CROSSLINKED HYDROPHILIC POLYMER, A SURFACTANT HAVING AN HLB LESS THAN OR EQUAL TO 5 AND A SILICONE COPOLYMER | July 2021 | November 2024 | Abandon | 40 | 4 | 1 | No | No |
| 17423331 | DIESTER OF PLANT-BASED 1,3-PROPANEDIOL | July 2021 | November 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17415663 | OIL-IN-WATER COSMETIC AND METHOD FOR PRODUCING THE SAME | June 2021 | April 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17319325 | DPP IV INHIBITOR FORMULATIONS | May 2021 | June 2024 | Allow | 37 | 2 | 1 | No | No |
| 17187512 | METHODS AND COMPOSITIONS USING SYNTHETIC NANOCARRIERS COMPRISING IMMUNOSUPPRESSANT | February 2021 | February 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17267332 | EMULSION COSMETIC | February 2021 | May 2025 | Allow | 52 | 6 | 0 | Yes | No |
| 17266567 | ANTIOXIDANT COMPOSITION COMPRISING NOVEL GINSENOSIDE | February 2021 | October 2024 | Abandon | 44 | 2 | 0 | No | No |
| 16973904 | PERSONAL CARE FORMULATIONS COMPRISING THICKENED ORGANIC LIQUIDS | December 2020 | November 2024 | Abandon | 48 | 5 | 1 | No | No |
| 16982338 | RAW MATERIAL FOR COSMETIC AND OIL-IN-WATER EMULSION COSMETIC COMPRISING CORE-CORONA POLYMER PARTICLE | September 2020 | November 2024 | Abandon | 50 | 4 | 0 | Yes | Yes |
| 16975418 | POROUS BIOMATERIALS FOR TISSUE REGENERATION | August 2020 | November 2024 | Allow | 51 | 5 | 0 | No | No |
| 16909635 | TABLETS CONTAINING ARGININE AT HIGH CONCENTRATION | June 2020 | May 2025 | Abandon | 59 | 7 | 0 | Yes | No |
| 16954402 | ANTIMICROBIAL LAYERED MATERIAL | June 2020 | September 2024 | Allow | 51 | 4 | 1 | Yes | No |
| 16635372 | Treatment of Mosaic Viruses and Bacterial Infections of Plants | January 2020 | October 2024 | Abandon | 57 | 5 | 0 | No | No |
| 16306096 | IMPROVED HAIR CARE COMPOSITIONS | November 2018 | March 2020 | Allow | 15 | 1 | 0 | No | No |
| 16035762 | ENHANCED EFFICIENCY OF SUNSCREEN COMPOSITIONS | July 2018 | July 2024 | Allow | 60 | 4 | 1 | No | Yes |
| 16065952 | Antifungal Agent | June 2018 | June 2020 | Abandon | 24 | 6 | 1 | Yes | Yes |
| 14818212 | METHOD OF SELECTING ANTIOXIDANTS FOR USE IN TOPICALLY APPLIED COMPOSITIONS | August 2015 | June 2018 | Allow | 35 | 4 | 0 | Yes | Yes |
| 13335151 | METHODS AND COMPOSITIONS FOR TREATING ACNE | December 2011 | August 2012 | Allow | 7 | 2 | 0 | Yes | No |
| 13103393 | HIGH PHOTOSTABILITY SUNSCREEN COMPOSITION | May 2011 | August 2013 | Allow | 27 | 1 | 0 | No | No |
| 12879413 | WATER-INSOLUBLE MEDICINE | September 2010 | November 2012 | Allow | 27 | 2 | 1 | Yes | No |
| 12511800 | SYNTHESIS OF NANOPARTICLES BY FUNGI | July 2009 | January 2013 | Allow | 41 | 2 | 1 | No | No |
| 12169764 | PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION OF POORLY SOLUBLE COMPOUNDS | July 2008 | May 2012 | Allow | 46 | 2 | 1 | No | Yes |
| 12149058 | Melt formula | April 2008 | May 2013 | Allow | 60 | 2 | 0 | No | No |
| 11722284 | INFECTION-RESISTANT POLYURETHANE FOAMS, METHOD FOR PRODUCING THE SAME AND USE THEREOF IN ANTISEPTIC WOUND DRESSINGS | June 2007 | December 2011 | Allow | 54 | 2 | 1 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner YU, HONG.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 30.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner YU, HONG works in Art Unit 1614 and has examined 44 patent applications in our dataset. With an allowance rate of 54.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner YU, HONG's allowance rate of 54.5% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by YU, HONG receive 2.55 office actions before reaching final disposition. This places the examiner in the 86% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by YU, HONG is 37 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +0.0% benefit to allowance rate for applications examined by YU, HONG. This interview benefit is in the 10% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 21.9% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 22.7% of cases where such amendments are filed. This entry rate is in the 21% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 62.5% of appeals filed. This is in the 35% percentile among all examiners. Of these withdrawals, 20.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 25.0% are granted (fully or in part). This grant rate is in the 15% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.